Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Hala H. Halawah, Nimer S. Alkhatib, Abdulaali R. Almutairi, Mohammad Saleh, Shiraz S. Halloush, Omar Rashdan, Lama Masadh, Osama H. Abusara & Ivo Abraham. (2023) Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan. Journal of Medical Economics 26:1, pages 835-842.
Read now
Read now
Consuela Cheriece Yousef, Mansoor Ahmed Khan, Hind Almodaimegh, Majed Alshamrani, Meteb Al-Foheidi, Hana AlAbdalkarim, Ahmed AlJedai, Anjum Naeem & Ivo Abraham. (2023) Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: simulation study. Journal of Medical Economics 26:1, pages 394-402.
Read now
Read now
Nimer S Alkhatib, Shiraz Halloush & Ivo Abraham. (2023) The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region. Expert Opinion on Biological Therapy 23:8, pages 671-677.
Read now
Read now
Michelle Shayne, R. Donald Harvey & Gary H. Lyman. (2021) Prophylaxis and treatment strategies for optimizing chemotherapy relative dose intensity. Expert Review of Anticancer Therapy 21:10, pages 1145-1159.
Read now
Read now
Ali McBride, Karen MacDonald, Adolfo Fuentes-Alburo & Ivo Abraham. (2021) Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer. Journal of Medical Economics 24:1, pages 743-756.
Read now
Read now
Ali McBride, Karen MacDonald, Adolfo Fuentes-Alburo & Ivo Abraham. (2021) Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment. Journal of Medical Economics 24:1, pages 598-606.
Read now
Read now
Karen MacDonald, Ali McBride, Neda Alrawashdh & Ivo Abraham. (2020) Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv. Journal of Medical Economics 23:12, pages 1466-1476.
Read now
Read now
Ali McBride, Weijia Wang, Kim Campbell, Sanjeev Balu, Karen MacDonald & Ivo Abraham. (2020) Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim. Journal of Medical Economics 23:8, pages 856-863.
Read now
Read now
Kashyap B Patel, Luiz H Arantes$suffix/text()$suffix/text(), Wing Yu Tang & Selwyn Fung. (2018) The role of biosimilars in value-based oncology care. Cancer Management and Research 10, pages 4591-4602.
Read now
Read now
Lee S Schwartzberg, Lincy S Lal, Sanjeev Balu, Kim Campbell, Lee Brekke, Caitlin Elliott & Stephanie Korrer. (2018) Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar. ClinicoEconomics and Outcomes Research 10, pages 493-500.
Read now
Read now
Ali McBride, Kim Campbell, Mohan Bikkina, Karen MacDonald, Ivo Abraham & Sanjeev Balu. (2018) Reply: Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. Journal of Medical Economics 21:6, pages 606-609.
Read now
Read now
Mark Bensink, Christine Edwards, Charles Bowers & Jon Campbell. (2018) Response to: McBride A, Campbell K, Bikkina M, et al. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. J Med Econ 2017;20:1083–93. Journal of Medical Economics 21:6, pages 603-605.
Read now
Read now
Articles from other publishers (17)
Sylvia A. van Laar, Kim B. Gombert-Handoko, Sophie Wassenaar, Judith R. Kroep, Henk-Jan Guchelaar & Juliette Zwaveling. (2022) Real-world evaluation of supportive care using an electronic health record text-mining tool: G-CSF use in breast cancer patients. Supportive Care in Cancer 30:11, pages 9181-9189.
Crossref
Crossref
Douglas W. Blayney & Lee Schwartzberg. (2022) Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review. Cancer Treatment Reviews 109, pages 102427.
Crossref
Crossref
Tim Schauer, Pernille Hojman, Julie Gehl & Jesper Frank Christensen. (2020) Exercise training as prophylactic strategy in the management of neutropenia during chemotherapy. British Journal of Pharmacology 179:12, pages 2925-2937.
Crossref
Crossref
Ali McBride, Neda Alrawashdh, Karen MacDonald & Ivo Abraham. (2022) Expanded access to anticancer treatments from conversion to biosimilar pegfilgrastim-cbqv in US breast cancer patients. Future Oncology 18:3, pages 363-373.
Crossref
Crossref
Jentora WhiteAfton WagnerHima Patel. (2022) The impact of biosimilar insulins on the diabetes landscape. Journal of Managed Care & Specialty Pharmacy 28:1, pages 91-98.
Crossref
Crossref
Karen MacDonald, Neda Alrawashdh, Ali McBride & Ivo Abraham. (2021) Conversion to biosimilar pegfilgrastim-cbqv enables budget-neutral access to FOLFIRINOX treatment for metastatic pancreatic cancer. Future Oncology 17:33, pages 4561-4570.
Crossref
Crossref
Ali McBride, Karen MacDonald & Ivo Abraham. (2021) Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to R-CHOP treatment in non-Hodgkin lymphoma. Leukemia Research 106, pages 106591.
Crossref
Crossref
Lauren D Curry, Brandi Anders, Emily V Dressler & LeAnne Kennedy. (2020) Efficacy of a conversion from filgrastim to filgrastim-sndz in stem cell transplant patients undergoing mobilization. Journal of Oncology Pharmacy Practice 27:4, pages 871-876.
Crossref
Crossref
Kaniz Afroz Tanni, Cong Bang Truong, Sura Almahasis & Jingjing Qian. (2021) Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. BioDrugs 35:2, pages 239-254.
Crossref
Crossref
Bruna de Oliveira Ascef, Ana Carolina de Freitas Lopes & Patrícia Coelho de Soárez. (2020) Health technology assessment of biosimilars worldwide: a scoping review. Health Research Policy and Systems 18:1.
Crossref
Crossref
Saurabh Talathi & Kondal R. Kyanam Kabir Baig. (2020) Biosimilars in inflammatory bowel disease. Journal of Digestive Diseases 21:11, pages 610-620.
Crossref
Crossref
Kai Hübel, Florian Kron & Michael Patrick Lux. (2020) Biosimilars in oncology: Effects on economy and therapeutic innovations. European Journal of Cancer 139, pages 10-19.
Crossref
Crossref
Jie ZhangGayathri SridharCharles E. BarrBernadette EichelbergerCatherine M. LockhartJames MarshallJerry ClewellNeil A. AccorttJeffrey R. CurtisCynthia HolmesCheryl N. McMahill-WalravenJeffrey S. BrownKevin Haynes. (2020) Incidence of Serious Infections and Design of Utilization and Safety Studies for Biologic and Biosimilar Surveillance. Journal of Managed Care & Specialty Pharmacy 26:4, pages 417-490.
Crossref
Crossref
Roberto Ravasio, Lorenzo Antonuzzo, Marco Danova & Paolo Pronzato. (2020) A Budget impact analysis of pegfilgrastim biosimilar in the treatment of febrile neutropenia in Italy. AboutOpen 7:1, pages 4-8.
Crossref
Crossref
Ari Brekkan, Luis Lopez-Lazaro, Elodie L. Plan, Joakim Nyberg, Suresh Kankanwadi & Mats O. Karlsson. (2019) Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies. The AAPS Journal 21:5.
Crossref
Crossref
Lee S. SchwartzbergLincy S. Lal, Sanjeev BaluKim CampbellLee Brekke, Andrew DeLeonCaitlin Elliott & Stephanie Korrer. (2018) Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy. Journal of Managed Care & Specialty Pharmacy 24:10, pages 976-984.
Crossref
Crossref
Ali McBride, Sanjeev Balu, Kim Campbell, Mohan Bikkina, Karen MacDonald & Ivo Abraham. (2017) Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz. Future Oncology 13:25, pages 2285-2295.
Crossref
Crossref